By Stephen Beech

A new antibiotic to fight the deadly " superbug " C. diff has proved effective in clinical trials.

Treating patients with ibezapolstat provided high rates of "sustained" clinical cures, say American scientists.

As the effectiveness of antibiotics meant to fight Clostridioides difficile, or C. diff, wanes, researchers at the University of Houston saw positive results when testing the antibiotic.

C. diff is the leading cause of death from gastroenteritis in the United States, causing an estimated 453,000 infections yearly and 29,300 deaths.

Rates of C. diff in the UK have increased every year since 2021, reaching 29.5 cases per 100,000 population in England in 2023/2024.

The bacterial infection causes gastrointestinal illness, ranging from diarrhea and abdominal pa

See Full Page